Janssen&Janssen schreef op 8 mei 2023 23:55:
Onze “vrinden” van pharvaris hebben vandaag hun cijfers bekend gemaakt:
ir.pharvaris.com/news-releases/news-r...First Quarter 2023 Financial Results
Liquidity Position. Cash and cash equivalents were €135 million as of March 31, 2023, compared to €162 million for December 31, 2022.
Research and Development (R&D) Expenses. R&D expenses were €13.7 million for the quarter ended March 31, 2023, compared to €13.5 million for the quarter ended March 31, 2022.
General and Administrative (G&A) Expenses. G&A expenses were €7.3 million for the quarter ended March 31, 2023, compared to €5.9 million for the quarter ended March 31, 2022.
Loss for the year. Loss for the first quarter was €22.6 million, resulting in basic and diluted loss per share of €0.67, for the quarter ended March 31, 2023, compared to €16.0 million, or basic and diluted loss per share of €0.48, for the quarter ended March 31, 2022.
Non-clinical toxicology study ongoing. A 26-week rodent toxicology study, which is intended to provide additional data to address the clinical holds in the U.S., is ongoing; the results from which Pharvaris anticipates submitting to the U.S. Food and Drug Administration (FDA) by the end of 2023.
Ruim 1.5 jaar vertraging in het US gedeelte, ligt al vanaf augustus vorig jaar on hold.
Als ze er 30 miljoen per Q doorheen branden dan zijn ze met deze cash positie Q4/Q1 bijna failliet.
Zet de aandelen pers alvast maar aan voor deze toko.